drugset
drugset / Trial / NCT03931681

A Study of OKI-179 in Patients With Solid Tumors

NCT03931681 ↗

Phase 1 Completed 34 enrolled OnKure, Inc. University of Colorado, Denver · collab
NaSingle-groupOpen-labelTreatment

Summary

This study is a Phase 1, single center, open-label study, assessing single agent dose escalation of OKI-179.

Timeline

Start
2019-05-08
Primary completion
2021-11-27
Completion
2021-11-27

Drugs

EvaluationDrugModalityDoseRoute
Subject BOCODEPSIN Small molecule — Oral

Indications

cancer